These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34001791)

  • 1. Screening for Chemotherapy-induced Peripheral Neuropathy and Utilization of Physical Therapy in Pediatric Patients Receiving Treatment for Hematologic Malignancies.
    Wang CP; Syrkin-Nikolau M; Farnaes L; Shen D; Kanegaye M; Kuo DJ
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e358-e361. PubMed ID: 34001791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic.
    Kang L; Kadan-Lottick NS; Rotatori J; Kujawski SE; Messerschmidt E; Auerbach C; Balsamo LM; Lustberg MB; Ma X; Rodwin RL
    Semin Oncol Nurs; 2024 Oct; 40(5):151716. PubMed ID: 39164160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring clinical markers of Axon degeneration processes in Chemotherapy-induced peripheral neuropathy among young adults receiving vincristine or paclitaxel.
    Knoerl R; Mazzola E; Pazyra-Murphy M; Ryback B; Frazier AL; Freeman RL; Hammer M; LaCasce A; Ligibel J; Luskin MR; Berry DL; Segal RA
    BMC Neurol; 2024 Sep; 24(1):366. PubMed ID: 39342135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
    Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
    Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced neuropathy and pain in pediatric oncology patients: impact of combination therapies.
    Soriano D; Santos Chocler G; Varela MA; Coronel MF
    Eur J Pediatr; 2024 Sep; 183(9):3749-3756. PubMed ID: 38856761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia.
    Rodwin RL; Kairalla JA; Hibbitts E; Devidas M; Whitley MK; Mohrmann CE; Schore RJ; Raetz E; Winick NJ; Hunger SP; Loh ML; Hockenberry MJ; Angiolillo AL; Ness KK; Kadan-Lottick NS
    J Natl Cancer Inst; 2022 Aug; 114(8):1167-1175. PubMed ID: 35552709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
    Knoerl R; Weller E; Halpenny B; Berry D
    BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies.
    Youk J; Kim YS; Lim JA; Shin DY; Koh Y; Lee ST; Kim I
    PLoS One; 2017; 12(8):e0183491. PubMed ID: 28827818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
    Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
    BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
    Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
    Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
    Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
    Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.
    McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB
    J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice.
    Vasquez S; Guidon M; McHugh E; Lennon O; Grogan L; Breathnach OS
    Ir J Med Sci; 2014 Mar; 183(1):53-8. PubMed ID: 23832573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy.
    Saito T; Okamura A; Inoue J; Makiura D; Doi H; Yakushijin K; Matsuoka H; Sakai Y; Ono R
    Oncol Res; 2019 Mar; 27(4):469-474. PubMed ID: 30126466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
    Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches.
    Knoerl R; Smith EML; Han A; Doe A; Scott K; Berry DL
    Patient Educ Couns; 2019 Sep; 102(9):1636-1643. PubMed ID: 31003878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
    Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
    Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.